The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
Subscribe To Our Newsletter & Stay Updated
